Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
My laboratory is interested in mechanisms and therapy of cancers. In the past years, I have been working on different types of hematologic and solid cancers. Most lymphomas, but also an increasing number of solid tumors, are characterized by defined chromosomal translocations. The products of such translocations control tumor growth, confer precise biological characteristics to the tumors and can be targeted by specific therapies. In lymphoma, the translocations involving the Anaplastic Lymphoma Kinase (ALK) gene are characteristic of Anaplastic Large Cell Lymphoma (ALCL), but were recently found also in Non-Small Cell Lung Cancers (NSCLC) and other type of solid tumors. We have extensively studied the role of ALK in lymphoma and discovered multiple pathways essential to induce cellular transformation. By exploiting xenografts and mouse models for ALCL and NSCLC, and also neuroblastoma, we want to define relevant mechanisms of ALK-mediated transformation in vivo but also to validate therapeutic approaches to target ALK in such cancers. We are currently implementing innovative therapies such as ALK inhibitors, ALK-targeted siRNA and ALK-directed cancer immunotherapy. In this context, we developed a vaccination protocol that generates a strong ALK-specific immunization and seek to explore its potential use in clinical protocols.
Cancer Immunology, Lymphoma and Myeloma